🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Renal Physiology for the Clinician Series from @CJASN #Nephpearls 👉 journals.lww.com/cjasn/pages/co…

SGLT2 inhibitor (SGLT2i) Cold 🥶 Map: Indications for SGLT2i in CKD/ Albuminuria/ Type 2 Diabetes (T2D)/ Heart Failure (HFrEF, HFmrEF, HFpEF) from Int Society of Nephrology KDIGO RPA-Nephrology ASPC #Nephpearls #Cardiorenal 👉 theisn.org/initiatives/to…

Do you prescribe SGLT2 inhibitors (SGLT2i) for patients with ADPKD? #Nephpearls #AskRenal ❤️ LIKE for YES (and why?) ❌ X for NO (and why?) 👉 pubmed.ncbi.nlm.nih.gov/39099568/

Potential disease-specific effects of SGLT2 inhibitors (SGLT2i) in ADPKD: Benefit or risk? ca. 2025 #Nephpearls 👉 pubmed.ncbi.nlm.nih.gov/40199734/

Use of SGLT2 inhibitors (SGLT2i) in ADPKD is "not presently recommended," because people with ADPKD have been excluded from the clinical trials; thus, its safety has not been evaluated #Nephpearls 📌 The opinion of the KDIGO Work Group is that, "at the moment," the only

Genome-Wide Association Study of Quantitative Kidney Function in 52,531 Individuals with Diabetes Identifies Five D… JASN_News JBCole Jose Florez Congrats to the GENIE Team! pubmed.ncbi.nlm.nih.gov/40323663/

How to individualise renoprotective therapy in obese patients with chronic kidney disease ➡️a commentary by the Diabesity Working Group of the ERA ERA - European Renal Association 🔓doi.org/10.1093/ndt/gf…

Blood Pressure (BP) Management in the Patient with CKD ca. 2022 #Nephpearls #WorldHypertensionDay #WorldHypertensionDay2025 👉🏼 pubmed.ncbi.nlm.nih.gov/34987024/

Multiomic analysis of human kidney disease identifies a tractable inflammatory and pro-fibrotic tubular cell phenotype | ⁦Nature Communications⁩ nature.com/articles/s4146…

🚨Post-Transplant Diabetes Mellitus (PTDM) – more than just sugar! 🧬 Risk factors from HLA to HCV 💉 Immunosuppressives 🫀 Long-term hits: CV events, albuminuria, graft loss 👇 Must-see visual + keys points ! 📖 doi.org/10.1111/dom.15… #NephTwitter #Transplant #MedEd

This Core Curriculum explores commonly implicated pathophysiological mechanisms in kidney dysfunction in heart failure and discuss principles behind effective decongestion and assessment of adequacy of natriuresis: bit.ly/434spfa (FREE) Kevin Bryan Lo A. Janakiraman Janani Rangaswami

The VISIONARY trial of sibeprenlimab in IgA nephropathy is the first P3 trial of an APRIL inhibitor. Results being presented in as a late-breaker at ERA - European Renal Association next Friday by Vlado Perkovic I spoke with HCPLive about APRIL inhibitors and VISIONARY more specifically:

Ten Tips for an Onco-Nephrology Clinic doi.org/10.1093/ckj/sf…

🤔When to suspect Alport Syndrome doi.org/10.1093/ndt/gf… NDT Hans-Joachim Anders